Identification of cognitively impaired patients at risk for development of Alzheimer's disease dementia: an analysis of US Medicare claims data.

Background: Identifying factors associated with transitioning from mild cognitive impairment (MCI) to dementia due to Alzheimer's disease (AD dementia) or dementia due to any cause (all-cause dementia) may inform economic assessments of disease and early care planning.

Research Design And Methods: A multivariate logistic regression approach identified potential predictors of progression to AD dementia or all-cause dementia in individuals with MCI or cognitive impairment (CI). Eligible patients and variables of interest were identified using claims data from the Medicare Advantage Patient Database, by Optum.

Decision makers need an approach to determine digital therapeutic product quality, access, and appropriate use.

No funding was received for the writing of this article. Parcher is employed by Xcenda and has nothing to disclose. Coder is employed by Digital Therapeutics Alliance, which is a member of the USP Convention.

Evaluation of the cost-utility of a prescription digital therapeutic for the treatment of opioid use disorder.

The opioid epidemic continues to generate a significant mental and physical health burden on patients, and claims the life of almost 150 Americans daily. Making matters worse, an increase in relapses and/or opioid-related deaths has been reported in more than 40 U.S.

Single-injection HPLC method for rapid analysis of a combination drug delivery system.

Developing combination drug delivery systems (CDDS) is a challenging but necessary task to meet the needs of complex therapy regimes for patients. As the number of multi-drug regimens being administered increases, so does the difficulty of characterizing the CDDS as a whole. We present a single-step method for quantifying three model therapeutics released from a model hydrogel scaffold using high-performance liquid chromatography (HPLC).